Fusobacterium nucleatum regulates nicotinamide metabolism via the upregulation of NNMT to activate PARP1/MAPK signalling in colitis-associated cancer.

Authors

Jing Lei, Peiyu Yang, Feng Xu, Wenhao Su, Zihao Liu, Juan Li, Siyuan Chen, Yongyu Chen

Published in

Cellular and molecular life sciences : CMLS. May 30, 2026. Epub May 30, 2026.

Abstract

Colitis-associated cancer (CAC) is a serious complication of inflammatory bowel disease (IBD). Recent evidence has indicated that Fusobacterium nucleatum (F. nucleatum) may promote intestinal inflammation and carcinogenesis. However, the effects of F. nucleatum on the cancerous transformation of IBD, along with its underlying mechanisms, remain poorly understood. Our findings revealed that F. nucleatum was enriched in 57.1% of CAC tissues, which was higher than that in ulcerative colitis (UC, 53.0%), Crohn's disease (CD, 55.6%), and colorectal cancer (CRC, 53.7%) tissues. Furthermore, we demonstrated that F. nucleatum modulated nicotinamide (NAM) metabolism to promote the proliferation of CAC. Mechanistically, F. nucleatum upregulated NNMT to increase PARP1 expression, thereby activating MAPK signalling pathway. These findings provide insight into F. nucleatum-induced metabolic dysregulation and inflammatory cancer development and may propose novel intervention strategies for the prevention and treatment of microbial-associated inflammatory carcinogenesis.

PMID:
42223575
Bibliographic data and abstract were imported from PubMed on 01 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.